Recent clinical research has illuminated the path toward innovative therapies for chronic conditions, demonstrating the potential of targeted treatments across various diseases. Among these, the SCORPION trial, a phase 2 study in Japan, has shown promising results in treating non-small cell lung cancer (NSCLC) by combining docetaxel with ramucirumab as a second-line therapy, achieving an objective response rate (ORR) of 34.4% with manageable safety profiles. Similarly, the combination of sintilimab, a PD-1 targeting antibody, with albumin-bound paclitaxel for recurrent or metastatic cervical cancer has displayed notable antitumor activity, with an ORR of 44.4% and a disease control rate of 88.9%, despite the occurrence of manageable high-grade adverse events in nearly half of the participants. In the realm of gastrointestinal diseases, a multicenter cohort study highlighted the superior efficacy of ustekinumab over vedolizumab in treating Crohn's disease, achieving clinical and steroid-free remission at both 26 and 52 weeks, with comparable safety profiles. Adding to this landscape of targeted therapies, the study "Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer" introduces an innovative treatment regimen for refractory MSS metastatic colorectal cancer (mCRC), combining fecal microbiota transplantation (FMT) with anti-PD-1 and antiangiogenic therapies. This trial reported a median progression-free survival (PFS) of 9.6 months and overall survival (OS) of 13.7 months, with a manageable safety profile, highlighting the gut microbiome's significant role in enhancing immunotherapy efficacy. These studies collectively underscore the potential of combining targeted therapies to improve outcomes for patients with advanced cancers and chronic diseases, suggesting a shift towards more personalized and effective treatment strategies. However, the exploration of specific microbiome compositions and T-cell receptor (TCR) characteristics in the mCRC study also points to the importance of biomarker analysis in optimizing treatment responses, a theme that resonates with the need for further research to validate these findings and fully understand the implications of these therapies in the broader context of chronic disease treatment.